Drug Profile
Research programme: angiogenesis inhibitors - Celecure
Alternative Names: SB 101Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Angitia
- Developer Celecure
- Class Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Estonia
- 12 Feb 2008 SB 101 is available for licensing (http://www.celecure.com)
- 12 Feb 2008 Preclinical trials in Cancer in Estonia (unspecified route)